CP and COVID-19: Thus, we feel that further studies should be performed to investigate the role of CP in patients with previous treatment with B-cell-depleting monoclonal antibodies and COVID-19, with a focus in outcomes other than mortality, such as future readmissions for COVID-19, long-COVID-19, post-COVID-19 and quality of life.